Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK7653 in Chinese patients with impaired glucose tolerance
NCT04727580Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cofrogliptin in impaired glucose tolerance (IGT), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Mar 2021; status: completed.
02
Drugs
cofrogliptin
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT04727580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727580.